Search

The construction industry in Australia generates a significant amount of construction and demolition (C&D) waste, necessitating better waste management (WM) practices. This research addresses this issue by investigating CE strategies aimed at minimising C&D waste in Australian construction projects (CPs). Utilising a qualitative approach, the study is based on 20 interviews and four case studies of commercial CPs, analysed through NVivo content analysis. The findings emphasise the need to integrate CE strategies at every CP stage. In the pre-design phase, setting sustainable objectives and engaging stakeholders early is crucial for aligning goals to reduce C&D waste. The tendering process benefits from incorporating WM into contracts, demonstrating early commitment to sustainability. The design phase, through Building Information Modelling and designing for disassembly, offers substantial waste-reduction opportunities. Modular and prefabricated components during the construction phase enhance material reuse and recycling. Operational strategies like regular maintenance and retrofitting extend material lifespan, while selective demolition and digital cataloguing at the end-of-life phase enable efficient material recovery. This highlights the essential roles of policy, technology, and stakeholder collaboration in advancing CE practices, providing practical insights for construction professionals and policymakers to implement CE-related strategies in CPs. The research concludes that adopting CE strategies can lead to significant reductions in C&D waste and improved sustainability in the construction sector. [ABSTRACT FROM AUTHOR]

X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of various human malignancies. However, a comprehensive pan-cancer analysis investigating the prognostic value, immunological functions, and epigenetic associations of XRCC1 remains lacking. To address this knowledge gap, we conducted a systematic investigation employing bioinformatics techniques across 33 cancer types. Our analysis encompassed XRCC1 expression levels, prognostic and diagnostic implications, epigenetic profiles, immune and molecular subtypes, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), immune checkpoints, and immune infiltration, leveraging data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases. Notably, XRCC1 displayed both positive and negative correlations with prognosis across different tumors. Epigenetic analysis revealed associations between XRCC1 expression and DNA methylation patterns in 10 cancer types, as well as enhanced phosphorylation. Furthermore, XRCC1 expression demonstrated associations with TMB and MSI in the majority of tumors. Interestingly, XRCC1 gene expression exhibited a negative correlation with immune cell infiltration levels, except for a positive correlation with M1 and M2 macrophages and monocytes in most cancers. Additionally, we observed significant correlations between XRCC1 and immune checkpoint gene expression levels. Lastly, our findings implicated XRCC1 in DNA replication and repair processes, shedding light on the precise mechanisms underlying its oncogenic effects. Overall, our study highlights the potential of XRCC1 as a prognostic and immunological pan-cancer biomarker, thereby offering a novel target for tumor immunotherapy.